




Pseudo-UTP

Ψ-UTP

Pseudouridine-5'-triphosphate, Sodium Salt

Cat. No.	Amount
NU-1139S	10 µl (100 mM)
NU-1139L	5 x 10 µl (100 mM)
NU-1139XL	100 µl (100 mM)



Structural formula of Pseudo-UTP

For general laboratory use.

Please centrifuge briefly before opening (volume ≤2 ml).

Shipping: shipped on gel packs

Storage Conditions: store at -20 °C

Short term exposure (up to 1 week cumulative) to ambient temperature possible.

Shelf Life: 12 months after date of delivery

Molecular Formula: C₉H₁₅N₂O₁₅P₃ (free acid)

Molecular Weight: 484.14 g/mol (free acid)

Exact Mass: 483.97 g/mol (free acid)

CAS#: 1175-34-4

Purity: ≥ 99 % (HPLC)

Form: solution in water

Color: colorless to slightly yellow

Concentration: 100 mM - 110 mM

pH: 7.5 ±0.5

Solubility: water

Spectroscopic Properties: λ_{max} 265 nm ±2 nm, ε 7.9 L mmol⁻¹ cm⁻¹ (Tris-HCl pH 7.5)

Related Products:

HighYield T7 RNA Synthesis Kit, #RNT-101

Selected References:

Anderson *et al.* (2012) Nucleofection induces transient eIF2α phosphorylation by GCN2 and PERK. *Gene Ther.* doi: 10.1038/gt.2012.5.

Green *et al.* (2012) Activation of autoreactive B cells by endogenous TLR7 and TLR3 RNA ligands. *J. Biol. Chem.* **287** (47):39789.

Karikó *et al.* (2012) Increased Erythropoiesis in Mice Injected With Submicrogram Quantities of Pseudouridine-containing mRNA Encoding Erythropoietin. *Mol Ther.* **20** (5):984.

Warren *et al.* (2012) Feeder-free derivation of human induced pluripotent stem cells with messenger RNA. *Sci Rep.* **2**:657.

Anderson *et al.* (2011) Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L. *Nucleic Acids Research.* **39** (21):9329.

Karikó *et al.* (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein encoding mRNA. *Nucleic Acids Research.* **39** (21):e142.

Anderson *et al.* (2010) Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. *Nucleic Acids Research.* **38** (17):5884.

Warren *et al.* (2010) Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA. *Cell Stem Cell.* doi:10.1016/j.stem.2010.08.012.

Karikó *et al.* (2008) Incorporation of Pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. *Molecular Therapy.* **16** (11):1833.

Belliot *et al.* (2005) Norovirus proteinase-polymerase and polymerase are both active forms of RNA-dependent RNA polymerase. *Journal of Virology.* **79** (4):2393.

Karikó *et al.* (2005) Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. *Immunity.* **23** (2):165.

Charette *et al.* (2000) Pseudouridine in RNA: what, where, how, and why. *IUBMB Life.* **49** (5):341.

Madore *et al.* (2000) Effect of modified nucleotides on Escherichia coli tRNA^{AGU} structure and on its aminoacylation by glutamyl-tRNA synthetase. Predominant and distinct roles of the mnm5 and s2 modifications of U34. *Eur J Biochem.* **266** (3):1128.

Goldberg *et al.* (1963) Comparative utilization of pseudouridine triphosphate and uridine triphosphate by ribonucleic acid polymerase. *J. Biol. Chem.* **238** (5):1793.